Home » Newsletters » BioWorld Science

BioWorld Science

April 3, 2014

View Archived Issues

Clinical data presented on sofosbuvir/ledipasvir fixed-dose combination for HCV

GlycoVaxyn designs new bioconjugates

Novel GPR119 agonists developed by Boehringer Ingelheim and Neurocrine Biosciences

Sanofi and Regeneron report data from phase II Japanese study of alirocumab

AstraZeneca and Medical Research Council establish collaboration

Almirall acquires European rights to InDex's ulcerative colitis drug candidate

New nAChR PAMs reported by Dainippon Sumitomo Pharma

FORMA Therapeutics and Celgene form multi-year strategic alliance

Astellas Pharma establishes regenerative medicine unit

Living Cell Technologies completes restructuring

New OPEN initiative aims to reinforce importance of biomarker testing in mCRC

Research agreement aims to identify biomarkers for SLE and lupus nephritis

Evotec and Convergence form alliance to discover novel analgesics

Evotec and Debiopharm collaborate in oncology drug discovery and development

Medesis Pharma and CEA sign collaborative agreement

Venaxis seeks FDA clearance of APPY1 Test for appendicitis

Cyclenium Pharma begins laboratory operations at the NEOMED Institute

Novel MPS1 inhibitors patented by Cancer Research Technology

Glenmark Pharmaceuticals discloses new ITK inhibitors

Array BioPharma and Amgen present novel glucokinase activator with improved profile

Immunovaccine and Pfenex report data from single-dose anthrax vaccine studies

Creabilis presents phase IIb data for CT-327 in psoriatic patients with chronic pruritus

ReGenX Biosciences and Avexis enter into agreement for NAV rAAV9 vectors

FDA grants fast track designation to Tetraphase Pharmaceuticals' eravacycline

Phase II results show safety and efficacy of VM-202 intramuscular injections in patients with CLI

EMA validates Keryx Biopharmaceuticals' MAA for Zerenex

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...